# Organic & Biomolecular Chemistry

# PAPER



Cite this: DOI: 10.1039/c5ob00545k

# Divergent synthesis of 4,6-diarylated pyridin-2(1*H*)-ones from chalcones: novel access to 2,4,6-triaryl pyridines<sup>†</sup>

Rajni Khajuria,<sup>a</sup> Prakash Kannaboina,<sup>b,c</sup> Kamal K. Kapoor,\*<sup>a</sup> Annah Gupta,<sup>a</sup> Gaurav Raina,<sup>b,c</sup> Amanpreet Kaur Jassal,<sup>d</sup> Love Karan Rana,<sup>d</sup> Maninder S. Hundal<sup>d</sup> and Parthasarathi Das\*<sup>b,c</sup>

A wide range of 4,6-diarylated/heterylated pyridin-2(1*H*)-one derivatives were synthesized in good to excellent yields from 1,3-diarylated/heterylated-2-propen-1-ones (chalcones) in one pot under metal and base-free conditions. This domino reaction suggests a novel mechanism comprising of Michael addition followed by amination, subsequent intramolecular amidation and finally dehydronitrosation. The usefulness of the designed 4,6-diarylated/heterylated pyridin-2(1*H*)-one derivatives has further been demonstrated by synthesizing medicinally important 2,4,6-triaryl/heteryl pyridines *via* Pd-catalyzed cross-coupling reaction.

Received 18th March 2015, Accepted 14th April 2015 DOI: 10.1039/c5ob00545k

www.rsc.org/obc

Published on 14 April 2015. Downloaded by Freie Universitaet Berlin on 01/05/2015 04:00:53.

## Introduction

The pyridin-2(1*H*)-one unit is a privileged heterocyclic motif, widely distributed in natural products and several biologically active synthetic compounds (Fig. 1).<sup>1</sup> Pyridin-2(1*H*)-one and its derivatives serve as ligands in co-ordination chemistry usually as 1,3 bridging ligand akin to carboxylate.<sup>2</sup> Apart from enjoying importance as bioactive molecules, substituted pyridin-2 (1*H*)-ones *viz.* 4,6-diarylated/heterylated pyridin-2(1*H*)-ones can be conceived as useful precursors for the synthesis of 2,4,6-triaryl/heteryl pyridines. The 2,4,6-triaryl pyridines serve as synthons in biologically active compounds (Fig. 1).<sup>3</sup> Further, due to their  $\pi$ -stacking ability, the importance of 2,4,6-triaryl pyridines in supramolecular chemistry is also well documented.<sup>4</sup>

In our pursuit to synthesize 4,6-disubstituted-3-nitropyridin-2(1*H*)-ones, we were encouraged by the work reported by Manna *et al.*, on the synthesis of 4,6-disubstituted-3-cyanopyridin-2(1*H*)-ones from chalcones, ammonium acetate and ethyl 2-cyanoacetate.<sup>5</sup> Therefore, we envisaged the replacement of

<sup>a</sup>Department of Chemistry, University of Jammu, Jammu 180006, India. E-mail: k2kapoor@yahoo.com




Fig. 1 Biologically active pyridin-2(1H)-ones and triaryl pyridines.


ethyl 2-cyanoacetate by ethyl 2-nitroacetate for the synthesis of 4,6-disubstituted-3-nitropyridin-2(1*H*)-one but to our surprise 4,6-disubstituted pyridin-2(1*H*)-one was obtained which lacked the nitro group at the 3-position. Thus, we became curious to probe the mechanism and scope of this reaction for the synthesis of 4,6-diarylated/heterylated pyridin-2(1*H*)-ones in the light of their significance in medicinal/materials chemistry, as well as precursors for 2,4,6-triarylpyridines. Literature survey revealed that there are several methods known for the synthesis of functionalized pyridin-2(1*H*)-ones<sup>6</sup> but a very few methods are available for the exclusive synthesis of 4,6-diarylated pyridin-2(1*H*)-ones.<sup>7</sup> Most of these methods<sup>7*a*-*c*</sup> rely on the Michael addition of 2-substituted acetamides to 1,3-diarylated-2-propen-1-ones followed by intramolecular cyclization



View Article Online

<sup>&</sup>lt;sup>b</sup>Academy of Scientific and Innovative Research (AcSIR), New Delhi 110001, India <sup>c</sup>Medicinal Chemistry Division, Indian Institute of Integrative Medicine (CSIR), Jammu 180001, India. E-mail: partha@iiim.ac.in

<sup>&</sup>lt;sup>d</sup>Department of Chemistry, Guru Nanak Dev University, Amritsar 143005, India † Electronic supplementary information (ESI) available: Spectroscopic data <sup>1</sup>H and <sup>13</sup>C NMR spectra for all compounds and X-ray data of compounds *viz.* 2a, 2c, 2e, 2j, 4 and 7e. CCDC 1013400, 1013398, 1013402, 1013399, 1013401 and 1029360. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c5ob00545k



Scheme 1 Synthesis of 4,6-diarylated pyridin-2(1H)-ones.




**Scheme 2** Synthesis of 4,6-diarylated/heterylated pyridin-2(1*H*)-ones and 2,4,6-triaryl/heteryl pyridines.

and elimination to yield 4,6-diarylated pyridin-2(1*H*)-ones (Scheme 1). It is pertinent to mention here the substitution of acetamide at the 2-position, which leads to a double bond while the amino group of acetamide serves as a 'nitrogen' source for the pyridin-2(1*H*)-one ring in the final product. These methods suffer from one or more of the drawbacks such as limited accessibility of starting materials, usage of a strong base, column chromatography for separation and purification of the final products, harsh reaction conditions and non-ecofriendly solvents.

Hence, we envisaged a one-pot reaction of 1,3-diarylated/ heterylated-2-propen-1-ones using the ethyl 2-nitroacetate (NO<sub>2</sub> group for the installation of a double bond) and ammonium acetate as a nitrogen source in the product. The aim of the present work was to develop an efficient divergent route to 4,6diarylated/heterylated pyridin-2(1*H*)-one framework from 1,3diarylated/heterylated-2-propen-1-ones and ethyl 2-nitroacetate, and subsequent conversion to 2,4,6-triaryl/heteryl pyridines *via* Suzuki coupling (Scheme 2).

### Results and discussion

In our earlier successful attempts<sup>8</sup> towards the synthesis of useful heterocyclic systems using 1,3-diarylated-2-propen-1ones as significant precursors, we now contemplated their use for the synthesis of 2,4,6-triaryl/heteryl pyridines *via* 4,6-diarylated/heterylated pyridin-2(1*H*)-ones (Scheme 2). Recently, we have reported the reductive cyclization of the Michael adduct ethyl 2-nitro-5-oxo-3,5-diarylated/heterylated pentanoates ( $\gamma$ -nitroketones) to ethyl 3,5-diarylated/heterylated-1*H*-pyrrole-




Scheme 3 Outcome of reaction between 1,3-diphenyl-2-propen-1one 1a and ethyl 2-nitroacetate with NH<sub>4</sub>OAc.

2-carboxylates under microwave conditions.<sup>9</sup> Inspired by these findings, we envisaged a domino three-component reaction of 1,3-diarylated/heterylated-2-propen-1-ones, ethyl 2-nitroacetate and ammonium acetate for the synthesis of 4,6-diarylated/heterylated pyridin-2(1*H*)-ones. Refluxing a mixture of 1,3-diphenyl-2-propen-1-one **1a** (1.0 equiv.), ethyl 2-nitroacetate (1.0 equiv.) and NH<sub>4</sub>OAc (2.0 equiv.) in ethanol (5.0 mL) for 3 h led to the formation of three products, which were separated by successive crystallization and characterized as ethyl 2-nitro-5-oxo-3,5-diphenylpentanoate<sup>10</sup> **3** (30%), 3,4-dihydro-3-nitro-4,6-diphenylpyridin-2(1*H*)-one **4** (23%) and 4,6-diphenylpyridin-2(1*H*)-one<sup>7c</sup> **2a** (15%) (Scheme 3).

Further to optimize the reaction conditions, a mixture of 1,3-diphenyl-2-propen-1-one 1a (1 equiv.) and ethyl 2-nitroacetate (1 equiv.) was refluxed in ethanol using 4-6 equiv. of NH<sub>4</sub>OAc. To our delight, exclusive formation of 2a was noticed with 6 equiv. of NH<sub>4</sub>OAc. The above experiment was also carried out by using various ammonia sources such as NH<sub>4</sub>OH, NH<sub>4</sub>NO<sub>3</sub>, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, NH<sub>4</sub>Cl, NH<sub>4</sub>HCO<sub>3</sub>, NH<sub>4</sub>H<sub>2</sub>PO<sub>4</sub>,  $(NH_4OOCH)_2$  and  $NH_4(OOCH)$ , and the results are depicted in Table 1. The best result was obtained with NH<sub>4</sub>OAc as the ammonia source (84%, entry 9, Table 1) while NH4OH, NH<sub>4</sub>NO<sub>3</sub>, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, NH<sub>4</sub>Cl and NH<sub>4</sub>HCO<sub>3</sub> (6 equiv. each) proved ineffective and the starting material was recovered intact (entries 1-5, Table 1). NH4H2PO4, (NH4OOCH)2 and NH<sub>4</sub>(OOCH) were less effective as the desired product 2a was isolated in poor yields (entries 6-8, Table 1). To further improve upon the yield of the product 2a, ethanol was replaced with various solvents such as MeOH, EtOH, iPrOH, nBuOH, CHCl<sub>3</sub>, CH<sub>3</sub>CN, 1:1 DMF: H<sub>2</sub>O, 1:1 EtOH: H<sub>2</sub>O, diglyme, 1,4dioxane and toluene (entries 9-19, Table 1) but EtOH remained the most suitable solvent for this transformation.

Under the optimized conditions, diversely substituted 1,3diarylated/heterylated-2-propen-1-ones (**1a–u**) were investigated (Table 2). 1,3-Diarylated-2-propen-1-ones bearing electron donating (Me, OMe) or electron withdrawing groups (Br, Cl, NO<sub>2</sub>) in both the phenyl rings (*para* or *meta* positions) were converted into their corresponding 4,6-diarylated pyridin-2 (1*H*)-ones (**2a–l**) efficiently (71–84% yields). It is notable that bromo-containing substrates react to yield the corresponding pyridin-2(1*H*)-ones (**2k** and **2m**) which along with other chloro derivatives (**2c**, **2f** and **2i–j**) can serve as suitable substrates for further modification of the pyridin-2(1*H*)-one moiety. The 1,3diarylated-2-propen-1-ones bearing di- or tri-substitutions on the phenyl ring gave the desired product (**2m–o**) in excellent yields. Further, to enhance the generality of this reaction,

#### Table 1 Optimization of reaction conditions<sup>a</sup>




Entry	Ammonia source	Solvent	Yield <sup>b</sup> (%)
1	NH₄OH	EtOH	n.r.
2	NH <sub>4</sub> NO <sub>3</sub>	EtOH	n.r.
3	$(NH_4)_2SO_4$	EtOH	n.r.
4	NH4Cl	EtOH	n.r.
5	NH <sub>4</sub> HCO <sub>3</sub>	EtOH	n.r.
6	$NH_4H_2PO_4$	EtOH	25
7	$(NH_4OOCH)_2$	EtOH	20
8	HCO <sub>2</sub> NH <sub>4</sub>	EtOH	40
9	NH <sub>4</sub> OAc	EtOH	84
10	NH <sub>4</sub> OAc	MeOH	n.r.
11	NH <sub>4</sub> OAc	iPrOH	45
12	NH <sub>4</sub> OAc	nBuOH	62
13	NH <sub>4</sub> OAc	$CHCl_3$	n.r.
14	NH <sub>4</sub> OAc	CH <sub>3</sub> CN	n.r.
15	NH <sub>4</sub> OAc	$1:1$ DMF: $H_2O$	n.r.
16	NH <sub>4</sub> OAc	$1:1$ EtOH: $H_2O$	n.r.
17	NH <sub>4</sub> OAc	Diglyme	n.r.
18	NH <sub>4</sub> OAc	1,4-Dioxane	15
19	NH <sub>4</sub> OAc	Toluene	20

<sup>*a*</sup> Reaction conditions: **1a** (1.0 mmol), ethyl 2-nitroacetate (1.0 mmol), NH<sub>3</sub> source (6.0 mmol), solvent (5.0 mL), 4 h. <sup>*b*</sup> Isolated yields; n.r. = no reaction.


various arylated/heterylated combinations were investigated under these optimized conditions. Interestingly, the corresponding arylated/heterylated (2q-s) and heterylated/heteroarylated (2t-u) pyridin-2(1*H*)-ones were isolated in excellent yields (84-94%). The construction of pyridin-2(1*H*)-ones bearing aryl and bi-cyclic substitutions (2p) was also achieved under these optimized conditions. Further the structure of the pyridin-2 (1*H*)-ones bearing different aryl rings have been confirmed by X-ray analysis (2a, 2c, 2e, 2j) (for details see the ESI†).

In order to have an insight into the mechanism of the reaction, Michael product 3 was refluxed in ethanol for 1 h with 2 equiv. of NH<sub>4</sub>OAc. The formation of 4 and 2a in the ratio 3 : 2 was noticed. Interestingly, in 4, H<sub>b</sub> and NO<sub>2</sub> are syn to each other as revealed by the J values  $({}^{3}J_{H_{a}H_{b}} = 16 \text{ Hz})$  and further corroborated by its X-ray data. Further, 4 also produced 2a upon refluxing in ethanol with 2 equiv. of NH<sub>4</sub>OAc. Finally to our delight, 4,6-diphenylpyridin-2(1H)-one 2a was the only product obtained from refluxing a mixture of 1,3-diphenyl-2propen-1-one 1a (1.0 equiv.) and ethyl 2-nitroacetate (1.0 equiv.) with 6.0 equiv. of NH<sub>4</sub>OAc in ethanol for 4 h. In light of these observations, the following mechanism is proposed (Scheme 4). 1,3-Diphenyl-2-propen-1-one 1a undergoes NH<sub>4</sub>OAc catalyzed Michael addition with ethyl 2-nitroacetate to give adduct 3, which upon base-promoted cyclization results in 3,4-dihydro-3-nitro-4,6-diphenyl pyridin-2(1H)-one 4 followed by the loss of  $H_2O$ , EtOH and aromatization of 4 (syn





 $^a$  Reaction conditions: 1 (1.0 mmol), ethyl 2-nitroacetate (1.0 mmol), NH<sub>3</sub>OAc (6.0 mmol), EtOH (5.0 mL), reflux.




Scheme 4 Plausible reaction mechanism for the formation of 2a.

elimination of  $H_bNO_2$ ) to yield the corresponding 4,6-diphenyl pyridin-2(1*H*)-one **2a**. To the best of our knowledge, this is *hitherto* the first report of Michael reaction of 1,3-diarylated/

heterylated-2-propen-1-ones with ethyl 2-nitroacetate in the presence of  $NH_4OAc$ .

After successful synthesis of 4,6-diarylated/heterylated pyridin-2(1H)-ones in one-pot, we focused on exploring conditions that would enable us to obtain 2,4,6-triaryl/heteryl pyridines. There are reports available for cross-coupling reactions at the C-2 position of pyridine.<sup>11</sup> However to the best of our knowledge, C-2 arylation has rarely been explored in the presence of the 4,6-diarylated pyridine system.<sup>12</sup> Therefore, finding the generalised cross-coupling conditions for C-2 arylation would be useful from a synthetic standpoint. Traditionally, organohalides were widely studied and broadly used as the electrophile, in Suzuki-Miyaura cross-coupling reactions in synthesizing heteroaromatic compounds.13 Development of new electrophiles particularly C-O based electrophiles as a cross-coupling partner in Suzuki-Miyaura coupling reaction has attracted interest from various research groups.14 The advantage of using phenol derivatives as aryl electrophiles is apparent, as they are often readily available and are inexpensive. Initial reports toward achieving this goal employed aryl triflates as electrophiles.<sup>15</sup> The present use of tosylates as a cross-coupling partner would constitute a more robust methodology because these sulfonates are easy to handle and are generally stable to hydrolysis.<sup>16</sup> Therefore, we prepared O-tosyl derivatives of 4,6-disubstituted pyridin-2(1H)-ones, and the corresponding tosylated compounds were isolated in high yields (80-90%) (Scheme 5).17

Initial optimization studies were performed with 4,6-diphenyl pyridin-2-yl 4-methylbenzenesulfonate **6a** and phenylboronic acid as a cross-coupling partner in the presence of Pd(PPh<sub>3</sub>)<sub>4</sub> (10 mol%), and Na<sub>2</sub>CO<sub>3</sub> as a base in 1,4-dioxane at 100 °C, and **7a** was isolated in only 10% yield (entry 1,







Table 3). When we performed the reaction in combination with PPh<sub>3</sub> (10 mol%) as a ligand, and Na<sub>2</sub>CO<sub>3</sub> as a base in 1,4dioxane/H<sub>2</sub>O at 100 °C, formation of the desired product was not observed even after 24 h (entry 2, Table 3). Several ligands and bases were examined with variations in time and temperature (entries 3–12, Table 3). As depicted in Table 2, when NaOH was used in combination with Pd(OAC)<sub>2</sub> and XPhos at 100 °C in *n*BuOH/EtOH/H<sub>2</sub>O (6:1:1), the isolated yield was 65% (entry 8, Table 3). Further screening of different ligand systems such as PPh<sub>3</sub>, dppf, JPhos, PCy<sub>3</sub> (entries 3–5 and 12, Table 3) and bases such as KOH, KF, K<sub>3</sub>PO<sub>4</sub> (entries 9–12, Table 2) respectively remained less effective. Further use of different Pd-catalysts (entries 12 and 13, Table 3) resulted in lower yield. Lower yields were also obtained when we changed the solvent system to *t*AmOH/EtOH/H<sub>2</sub>O (6/1/1) (entry 9, Table 3).

Table 3         Optimization studies for C-2 arylation <sup>a</sup>								
Pd-Catalyst /L base, solvent 6a 7a								
Entry	Cat (10 mol%)	L	Base	Solvent	Yield (%)			
1	$Pd(PPh_3)_4$	_	$Na_2CO_3$	1,4-Dioxane	10			
2	$Pd(PPh_3)_4$	$PPh_3$	$Na_2CO_3$	1,4-Dioxane/H <sub>2</sub> O (7/3)	n.r			
3	$Pd(OAc)_2$	$PPh_3$	$K_3PO_4$	1,4-Dioxane	10			
4	$Pd(OAc)_2$	Dppf	$K_3PO_4$	tAmOH	15			
5	$Pd(OAc)_2$	Jphos	$K_3PO_4$	tAmOH	10			
6	$Pd(OAc)_2$	Xphos	$K_3PO_4$	tAmOH	40.			
7	$Pd(OAc)_2$	Xphos	NaOH	$t \text{AmOH/H}_2 \text{O} (4/1)$	42			
8	$Pd(OAc)_2$	Xphos	NaOH	$nBuOH/EtOH/H_2O(6/1/1)$	<b>70</b> $(65)^b$			
9	$Pd(OAc)_2$	Xphos	NaOH	tAmOH/EtOH/H <sub>2</sub> O (6/1/1)	40			
10	$Pd(OAc)_2$	Xphos	KOH	$nBuOH/EtOH/H_2O(6/1/1)$	35			
11	$Pd(OAc)_2$	Xphos	KF	$nBuOH/EtOH/H_2O(6/1/1)$	40			
12	Pd(dppf)Cl <sub>2</sub>	Xphos	$K_3PO_4$	$nBuOH/EtOH/H_2O(6/1/1)$	Trace			
13	$Pd_2(dba)_3$	PCy <sub>3</sub>	$K_3PO_4$	$nBuOH/EtOH/H_2O(6/1/1)$	10			

<sup>*a*</sup> Reaction conditions: **6a** (1.0 equiv.), phenylboronic acid (1.2 equiv.), cat. Pd (10 mol %), L (10 mol %), base (2 equiv.), solvent (1.0 mL). <sup>*b*</sup> Isolated yield, reaction performed under  $N_2$  atmosphere, n.r. = no reaction.

Table 4 Pd-catalysed C-2 arylation 4,6-diphenylpyridin-2-yl of 4-methylbenzene sulfonate<sup>a</sup>



<sup>a</sup> Reaction conditions: 6a (1.0 equiv.), phenylboronic acid (1.2 equiv.), Pd(OAc)<sub>2</sub> (10 mol %), X-Phos (10 mol %), NaOH (2 equiv.), nBuOH/ EtOH/H<sub>2</sub>O (6:1:1, 1.0 mL).

With the optimized protocol in hand, the scope of the cross-coupling reactions was explored using various aryl/ heterylboronic acids with differently substituted 4,6-diphenylpyridin-2-yl 4-methylbenzenesulfonate (Table 4). For example, electron-donating (7b-c, 7g) and electron-withdrawing phenylboronic acids (7h) all afforded C-2 arylated derivatives in good yields. In addition to substituted phenylboronic acids, benzo-[*d*][1,3]dioxol-5-ylboronic acid (7**d**, 7**f**) and heterocyclic boronic acid (7i) were also investigated under these conditions. This route thus offers significant flexibility to access these important heteroaromatic frameworks with unexplored and/or otherwise challenging substitution patterns. As an example, structurally diverse 2,4,6-triarylpyridine 7f is an important structural motif in designed compounds with interesting biological properties<sup>18</sup> synthesized in good yield (50%). In this context, X-ray crystal structure analysis of 2,6-diphenyl-4-(3,4,5trimethoxyphenyl) pyridine 7e was studied (see the ESI<sup>†</sup>).

# Conclusion

In summary, we have developed metal/base-free synthesis of 4,6-diarylated/heterylated pyridin-2(1H)-ones from 1,3-diarylated/heterylated-2-propen-1-ones. This protocol is general and efficient with respect to diverse substrates. The successful implementation of this synthetic strategy would imply developing a new route by overcoming the difficulties associated with previous methods, providing an alternative protocol to 4,6-diarylated pyridin-2(1H)-ones. This paper further reports the synthesis of 2,4,6-triaryl pyridines. This Pd-catalyzed strategy based on C-O activation of tosylates affords a complementary way to obtain aryl/heteryl functionalized molecules, known to be of great interest because of their biological/material properties. Finally, these two new protocols and their mechanistic understanding will definitely open a route to synthesizing the triaryl/heteryl structural motif in a programmed manner.

#### **Experimental**

#### General information

Melting points were uncorrected. <sup>1</sup>H and <sup>13</sup>C NMR spectra in CDCl<sub>3</sub> and DMSO-d<sub>6</sub> were recorded on Bruker Avance III-400 MHz, using (CH<sub>3</sub>)<sub>4</sub>Si as an internal standard. Chemical shifts ( $\delta$ ) are expressed in parts per million referenced to the residual solvent (*i.e.*, <sup>1</sup>H 7.24 ppm, <sup>13</sup>C 77.1 ppm for CDCl<sub>3</sub>; <sup>1</sup>H 2.50 ppm, <sup>13</sup>C 39.5 ppm for DMSO-d<sub>6</sub>). Signal multiplicity is expressed as follows: s (singlet), br s (broad singlet), d (doublet), t (triplet), g (guartet), m (multiplet). J values are given in hertz (Hz). For the HRMS measurement, Q-TOF was used. All reactions and purity of the synthesized compounds were monitored by TLC using silica gel 60 F254 aluminium plates. Visualization was accomplished by UV light, exposure to iodine vapours and by treating the plates with Dragendorff reagent followed by heating. Crystals suitable for X-ray single crystal analyses were obtained by EtOH. X-ray data were collected on a Bruker Kappa Apex-II diffractometer at RT with Mo-Ka radiation ( $\lambda = 0.71073$  Å) at the Department of Chemistry, Center for Advanced Studies, Guru Nanak Dev University, Amritsar. These were reduced applying Lorentz and polarization corrections as well as an absorption correction. Multiscan structures were solved by direct methods (SIR-92)<sup>19</sup> and refined by full-matrix least squares on  $F^2$  (SHELX 97).<sup>20</sup> All the non-H atoms were treated anisotropically and all H atoms were attached geometrically. Unless otherwise indicated, materials and solvents were purchased and used without further purification. 1,3-Diarylated/heterylated-2-propen-1-ones 1a-u were prepared according to the reported procedure.<sup>21</sup>

#### General procedures

Synthesis of 4,6-diarylated/heterylated pyridin-2(1H)-one derivatives 2a-u (general procedure A). A mixture of 1,3-diarylated/heterylated-2-propen-1-one (1a-u) (1.0 mmol), ethyl 2-nitroacetate (1.0 mmol) and ammonium acetate (6.0 mmol) in ethanol (5.0 mL) was refluxed for the appropriate time (Table 2). The reaction mixture was cooled to room temperature and the solid obtained was filtered, washed with ethanol, dried and recrystallized from ethanol to obtain the pure product (2a-u).

Organic & Biomolecular Chemistry

**4,6-Diphenylpyridin-2(1***H***)-one (2a). The title compound 2a was obtained from (2***E***)-1,3-diphenyl-2-propen-1-one <b>1a** (1.0 mmol) as a brown solid (0.207 g, 84% yield); mp 206–207 °C (lit.<sup>7c</sup> 203–204 °C); <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.77 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.89 (dd, *J* = 7.5, 1.9 Hz, 2H), 7.81 (dd, *J* = 7.8, 1.5 Hz, 2H), 7.53–7.48 (m, 6H), 6.99 (s, 1H), 6.67 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>)  $\delta$  164.2, 152.3, 148.7, 137.8, 134.8, 130.1, 129.9, 129.4, 129.2, 127.0, 127.3, 113.1, 104.9; IR (KBr): 3440.28, 1642.58 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>17</sub>H<sub>14</sub>NO [M + H]<sup>+</sup>, 248.1070; found: 248.1058.

**4-(4-Methylphenyl)-6-phenylpyridin-2(1***H***)-one (2b). The title compound <b>2b** was obtained from (*E*)-1-phenyl-3-(4-methylphenyl)-2-propen-1-one **1b** (1.0 mmol) as a shiny green solid (0.217 g, 83% yield); mp 233–234 °C (lit.<sup>7b</sup> 238–240 °C); <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 11.68 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.89 (d, *J* = 6.3 Hz, 2H), 7.72 (d, *J* = 7.9 Hz, 2H), 7.50 (d, *J* = 6.2 Hz, 3H), 7.32 (d, *J* = 7.9 Hz, 2H), 6.97 (s, 1H), 6.64 (s, 1H), 2.37 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 164.2, 152.1, 139.5, 134.9, 130.0, 129.1, 127.4, 127.2, 112.5, 104.8, 21.2; IR (KBr): 3235.62, 1613.47 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>18</sub>H<sub>16</sub>NO [M + H]<sup>+</sup>, 262.1226; found: 262.1228.

**4-(4-Chlorophenyl)-6-phenylpyridin-2(1***H***)-one (2c). The title compound 2c was obtained from (***E***)-3-(4-chlorophenyl)-1-phenyl-2-propen-1-one 1c (1.0 mmol) as a pale-yellow solid (0.242 g, 81% yield); mp 232–234 °C (lit.<sup>7***a***</sup> 237–238 °C); <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 11.78 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.91–7.85 (m, 4H), 7.57–7.49 (m, 5H), 7.01 (s, 1H), 6.68 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) 164.1, 150.9, 136.6, 134.7, 130.1, 129.4, 129.2, 129.2, 127.5, 113.0, 104.8; IR (KBr): 3441.15, 1644.48 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>17</sub>H<sub>13</sub>ClNO [M + H]<sup>+</sup>, 282.0680; found: 282.0680.** 

**4-(3-Nitrophenyl)-6-phenylpyridin-2(1***H***)-one (2d). The title compound 2d was obtained from (***E***)-3-(3-nitrophenyl)-1-phenyl-2-propen-1-one 1d (1.0 mmol) as a brown solid (0.225 g, 77% yield); mp 247–249 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 11.83 (br s, 1H, exchangeable with D<sub>2</sub>O), 8.57 (s, 1H), 8.33–8.26 (m, 2H), 7.95–7.91 (m, 2H), 7.80 (t,** *J* **= 8.0 Hz, 1H), 7.51 (d,** *J* **= 5.9 Hz, 3H), 7.13 (s, 1H), 6.79 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 164.1, 150.1, 148.8, 139.6, 134.9, 134.0, 131.0, 130.2, 129.1, 127.5, 124.4, 122.1, 113.6, 105.1; IR (KBr): 3442.95, 1651.33 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>17</sub>H<sub>13</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 293.0921; found: 293.0919.** 

**6-(4-Methoxyphenyl)-4-phenylpyridin-2(1***H***)-one (2e). The title compound 2e was obtained from (***E***)-1-(4-methoxyphenyl)-3-phenyl-2-propen-1-one 1e (1.0 mmol) as a pale-yellow solid (0.208 g, 75% yield); mp 248–250 °C (lit.<sup>7c</sup> 247–251 °C); <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 11.76 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.83 (dd,** *J* **= 24.5, 8.0 Hz, 4H), 7.50 (d,** *J* **= 5.1 Hz, 3H), 7.05 (d,** *J* **= 7.8 Hz, 2H), 6.90 (s, 1H), 6.59 (s, 1H), 3.83 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 164.2, 160.9, 152.3, 138.0, 129.8, 129.4, 128.9, 127.3, 114.6, 103.8, 55.8; IR (KBr): 3442.45, 1643.38 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>18</sub>H<sub>16</sub>NO<sub>2</sub> [M + H]<sup>+</sup>, 278.1176; found: 278.1186.** 

6-(4-Chlorophenyl)-4-phenylpyridin-2(1*H*)-one (2f). The title compound 2f was obtained from (*E*)-1-(4-chlorophenyl)-3-

phenyl-2-propen-1-one **1f** (1.0 mmol) as a grey solid (0.222 g, 79% yield); mp 260 °C (lit.<sup>7b</sup> 262–264 °C); <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.70 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.97 (d, J = 8.5 Hz, 2H), 7.85–7.80 (m, 2H), 7.54 (dd, J = 24.0, 8.1 Hz, 5H), 7.13 (s, 1H), 6.72 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>)  $\delta$  164.2, 152.2, 137.8, 134.7, 129.9, 129.4, 129.3, 129.1, 127.4, 112.4, 106.0; IR (KBr): 3441.68, 1645.48 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>17</sub>H<sub>13</sub>ClNO [M + H]<sup>+</sup>, 282.0680; found: 282.0731.

**6-(4-Methoxyphenyl)-4-(4-methylphenyl)pyridin-2(1***H***)-one (2g). The title compound 2g was obtained from (***E***)-1-(4-meth-oxyphenyl)-3-(4-methyl)-2-propen-1-one 1g (1.0 mmol) as a shiny brown solid (0.218 g, 75% yield); mp 254–256 °C (lit.<sup>7a</sup> 258–260 °C); <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 11.74 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.85 (d, J = 8.7 Hz, 2H), 7.70 (d, J = 8.1 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.05 (d, J = 8.8 Hz, 2H), 6.88 (s, 1H), 6.56 (s, 1H), 3.82 (s, 3H), 2.36 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 164.2, 160.9, 152.2, 139.5, 135.0, 130.1, 130.0, 129.7, 128.9, 127.5, 127.2, 114.5, 103.5, 55.7, 21.2; IR (KBr): 3083.71, 1632.46 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>19</sub>H<sub>18</sub>NO<sub>2</sub> [M + H]<sup>+</sup>, 292.1332; found: 292.1323.** 

**4,6-Bis(4-methoxyphenyl)pyridin-2(1***H***)-one (2h).** The title compound **2h** was obtained from (*E*)-1,3-bis(4-methoxyphenyl)-2-propen-1-one **1h** (1.0 mmol) as a black solid (0.236 g, 77% yield); mp 280–281 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) 12.00 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.77 (d, *J* = 8.7 Hz, 2H), 7.66 (d, *J* = 8.7 Hz, 1H), 7.39 (d, *J* = 8.7 Hz, 1H), 7.00 (t, *J* = 7.0 Hz, 4H), 6.72 (s, 1H), 6.50 (d, *J* = 10.4 Hz, 1H), 3.80 (s, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>)  $\delta$  164.2, 160.9, 152.2, 148.1, 139.5, 135.0, 130.0, 128.9, 127.2, 127.0, 114.6, 112.0, 103.5, 55.8; IR (KBr): 3437.23, 1639.30 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>19</sub>H<sub>18</sub>NO<sub>3</sub> [M + H]<sup>+</sup>, 308.1281; found: 308.1281.

**6-(4-Chlorophenyl)-4-(4-methyl)pyridin-2(1***H***)-one (2i). The title compound 2i was obtained from (***E***)-1-(4-chlorophenyl)-3-(4-methyl)-2-propen-1-one 1i (1.0 mmol) as a brown solid (0.233 g, 79% yield); mp 258–259 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 11.84 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.82 (dd,** *J* **= 26.9, 8.2 Hz, 4H), 7.56 (d,** *J* **= 8.4 Hz, 2H), 7.31 (d,** *J* **= 8.0 Hz, 2H), 6.94 (s, 1H), 6.63 (s, 1H), 2.37 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 164.1, 150.9, 141.5, 139.9, 136.7, 134.7, 129.9, 129.7, 129.6, 129.4, 129.2, 128.1, 127.3, 112.9, 104.1, 21.2; IR (KBr): 3401.12, 1689.24 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>18</sub>H<sub>15</sub>ClNO [M + H]<sup>+</sup>, 296.0837; found: 296.0841.** 

**6-(4-Chlorophenyl)-4-(4-methoxyphenyl)pyridin-2(1***H***)-one (2j). The title compound 2j was obtained from (***E***)-1-(4-chlorophenyl)-3-(4-methoxyphenyl)-2-propen-1-one 1j (1.0 mmol) as a reddish-brown solid (0.255 g, 82% yield); mp 294–295 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 11.60 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.95 (d,** *J* **= 8.6 Hz, 2H), 7.80 (d,** *J* **= 8.9 Hz, 2H), 7.56 (d,** *J* **= 8.7 Hz, 2H), 7.08 (s, 1H), 7.05 (d,** *J* **= 8.9 Hz, 2H), 6.66 (s, 1H), 3.82 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 164.2, 160.8, 151.6, 148.2, 134.7, 134.4, 129.8, 129.2, 129.1, 128.7, 114.8, 111.4, 105.5, 55.7; IR (KBr): 3442.18, 1658.53 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>18</sub>H<sub>15</sub>ClNO<sub>2</sub> [M + H]<sup>+</sup>, 312.0786; found: 312.0785.** 

**4-(4-Bromophenyl)-6-(4-chlorophenyl)pyridin-2(1H)-one** (**2k**). The title compound **2k** was obtained from (*E*)-3-

(4-bromophenyl)-1-(4-chlorophenyl)-2-propen-1-one **1k** (1.0 mmol) as a grey solid (0.298 g, 83% yield); mp 326–327 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.70 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.97 (d, J = 8.3 Hz, 2H), 7.80 (d, J = 8.0 Hz, 2H), 7.70 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 8.2 Hz, 2H), 7.14 (s, 1H), 6.73 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>)  $\delta$  164.2, 150.9, 136.9, 134.8, 134.2, 132.3, 129.5, 129.3, 129.1, 123.4, 112.1, 105.9; IR (KBr): 3437.44, 1658.80 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>17</sub>H<sub>12</sub>BrClNO [M + H]<sup>+</sup>, 359.9785; found: 359.9771.

**6-(4-Methoxyphenyl)-4-(4-nitrophenyl)pyridin-2(1***H***)-one (2l). The title compound 2l was obtained from (***E***)-1-(4-methoxyphenyl)-3-(4-nitrophenyl)-2-propen-1-one 1l (1.0 mmol) as a yellow solid (0.229 g, 71% yield); mp 297–299 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 11.81 (br s, 1H, exchangeable with D<sub>2</sub>O), 8.31 (d,** *J* **= 7.7 Hz, 2H), 8.08 (d,** *J* **= 7.8 Hz, 2H), 7.87 (d,** *J* **= 7.9 Hz, 2H), 7.05 (d,** *J* **= 8.0 Hz, 2H), 6.99 (s, 1H), 6.69 (s, 1H), 3.82 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 164.0, 161.0, 150.1, 148.2, 144.4, 131.6, 130.2, 129.0, 128.8, 124.4, 114.5, 113.4, 103.8, 55.8; IR (KBr): 3439.82, 1658.82 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>18</sub>H<sub>15</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 323.1026; found: 323.1006.** 

**4-(3-Bromo-4-methoxyphenyl)-6-phenylpyridin-2(1***H***)-one (<b>2m**). The title compound **2m** was obtained from (*E*)-3-(3-bromo-4-methoxyphenyl)-1-phenyl-2-propen-1-one **1m** (1.0 mmol) as a brown solid (0.288 g, 81% yield); mp 258–259 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 11.72 (br s, 1H, exchangeable with D<sub>2</sub>O), 8.11 (s, 1H), 7.94–7.85 (m, 3H), 7.51 (s, 3H), 7.23 (d, *J* = 8.5 Hz, 1H), 7.02 (s, 1H), 6.67 (s, 1H), 3.93 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 164.1, 156.8, 150.4, 148.7, 134.9, 131.7, 131.4, 130.1, 129.1, 128.2, 127.5, 113.3, 112.4, 111.8, 104.5, 56.9; IR (KBr): 3436.86, 1643.80 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>18</sub>H<sub>15</sub>BrNO<sub>2</sub> [M + H]<sup>+</sup>, 356.0281; found: 356.0273.

**4-(3,4,5-Trimethoxyphenyl)-6-phenylpyridin-2(1***H***)-one (2n). The title compound 2n was obtained from (***E***)-1-phenyl-3-(3,4,5-trimethoxyphenyl)-2-propen-1-one 1n (1.0 mmol) as a shiny brown solid (0.273 g, 81% yield); mp 288 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) \delta 11.76 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.89 (d,** *J* **= 5.3 Hz, 2H), 7.51 (s, 3H), 7.05 (s, 2H), 6.99 (s, 1H), 6.71 (s, 1H), 3.90 (s, 6H), 3.73 (s, 3H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) \delta 164.2, 153.6, 152.6, 148.3, 139.0, 134.7, 133.6, 130.1, 129.2, 127.5, 113.4, 104.8, 60.5, 56.5; IR (KBr): 3439.30, 1643.32 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>20</sub>H<sub>20</sub>NO<sub>4</sub> [M + H]<sup>+</sup>, 338.1387; found: 338.1383.** 

**6-(4-Methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)pyridin-2(1***H***)-one (20). The title compound 20 was obtained from (***E***)-1-(4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)-2-propen-1-one <b>10** (1.0 mmol) as a shiny green solid (0.308 g, 84% yield); mp 279–281 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 11.70 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.84 (d, *J* = 8.7 Hz, 2H), 7.07–7.01 (m, 4H), 6.89 (s, 1H), 6.62 (s, 1H), 3.88 (s, 6H), 3.82 (s, 3H), 3.71 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 164.2, 160.9, 153.6, 152.6, 147.9, 138.9, 133.7, 129.0, 126.9, 114.5, 112.7, 104.8, 103.9, 60.5, 56.5, 55.7; IR (KBr): 3265.89, 1640.63 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>21</sub>H<sub>22</sub>NO<sub>5</sub> [M + H]<sup>+</sup>, 368.1492; found: 368.1476. **6-(Benzo[d]**[1,3]**dioxol-5-yl)-4-phenylpyridin-2(1***H***)-one (2<b>p**). The title compound 2**p** was obtained from (*E*)-1-(benzo[*d*][1,3]-dioxo-5-yl)-3-phenyl-2-propen-1-one 1**p** (1.0 mmol) as a pale yellow solid (0.250 g, 86% yield); mp 326–327 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 11.66 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.81 (d, *J* = 6.7 Hz, 2H), 7.52–7.44 (m, 5H), 7.04 (d, *J* = 8.2 Hz, 1H), 6.95 (s, 1H), 6.61 (s, 1H), 6.11 (s, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 164.1, 152.3, 149.0, 148.2, 137.9, 129.8, 129.4, 127.3, 121.8, 108.9, 107.7, 102.0; IR (KBr): 3441.95, 1627.33 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>18</sub>H<sub>14</sub>NO<sub>3</sub> [M + H]<sup>+</sup>, 292.0968; found: 292.0964.

**4-Phenyl-6-(2-pyridyl)pyridin-2(1***H***)-one (2q).** The title compound 2**q** was obtained from (*E*)-3-phenyl-1-(pyridin-2-yl)-2-propen-1-one 1**q** (1.0 mmol) as a brown solid (0.213 g, 86% yield); mp 210–212 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 11.15 (br s, 1H, exchangeable with D<sub>2</sub>O), 8.72 (s, 1H), 8.32 (d, *J* = 8.0 Hz, 1H), 8.00 (t, *J* = 7.4 Hz, 1H), 7.84 (d, *J* = 7.0 Hz, 2H), 7.59–7.52 (m, 5H), 6.81 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 163.2, 152.3, 149.7, 138.1, 137.5, 130.0, 129.5, 127.3, 125.2, 121.4, 115.0, 105.1; IR (KBr): 3440.82, 1650.92 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>16</sub>H<sub>13</sub>N<sub>2</sub>O [M + H]<sup>+</sup>, 249.1022; found: 249.1013.

**4-(Furan-2-yl)-6-phenylpyridin-2(1***H***)-one (2r).** The title compound **2r** was obtained from (*E*)-3-(furan-2-yl)-1-phenyl-2-propen-1-one **1r** (1.0 mmol) as a light brown solid (0.223 g, 94% yield); mp 217–218 °C (lit.<sup>7b</sup> 212–214 °C); <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 11.67 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.91–7.83 (m, 3H), 7.53–7.48 (m, 3H), 7.37 (d, *J* = 3.4 Hz, 1H), 7.00 (s, 1H), 6.70 (dd, *J* = 3.3, 1.7 Hz, 1H), 6.62 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 164.0, 150.8, 145.6, 141.3, 134.5, 130.2, 129.2, 127.4, 113.0, 111.6, 108.8, 101.3; IR (KBr): 3437.54, 1641.40 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>15</sub>H<sub>12</sub>NO<sub>2</sub> [M + H]<sup>+</sup>, 238.0863; found: 238.0858.

**6-Phenyl-4-(thiophen-2-yl)pyridin-2(1***H***)-one (2s). The title compound 2s was obtained from (***E***)-1-phenyl-3-(thiophen-2-yl)-2-propen-1-one <b>1s** (1.0 mmol) as a shiny brown solid (0.225 g, 89% yield); mp 206–207 °C (lit.<sup>7b</sup> 202–204 °C); <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>)) δ 11.70 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.88 (d, *J* = 3.4 Hz, 3H), 7.76 (d, *J* = 5.0 Hz, 1H), 7.53 (d, *J* = 5.3 Hz, 3H), 7.25–7.23 (t, *J* = 4.2 Hz, 1H), 7.00 (s, 1H), 6.61 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 164.0, 148.8, 145.4, 140.6, 134.5, 130.2, 129.2, 129.0, 127.8, 127.4, 111.0, 103.3; IR (KBr): 3449.97, 1623.04 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>15</sub>H<sub>12</sub>NOS [M + H]<sup>+</sup>, 254.0634; found: 254.0635.

**4-(Furan-2-yl)-6-(thiophen-2-yl)pyridin-2(1***H***)-one (2t). The title compound 2t was obtained from (***E***)-3-(furan-2-yl)-1-(thiophen-2-yl)-2-propen-1-one 1t (1.0 mmol) as a brown solid (0.207 g, 85% yield); mp 241–243 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 11.40 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.88–7.86 (m, 2H), 7.68 (d,** *J* **= 4.9 Hz, 1H), 7.34–7.17 (m, 3H), 6.68 (s, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ 164.0, 150.8, 145.3, 141.2, 128.8, 126.8, 113.0, 111.0, 105.1, 102.5; IR (KBr): 3442.62, 1650.48 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>13</sub>H<sub>10</sub>NO<sub>2</sub>S [M + H]<sup>+</sup>, 244.0427; found: 244.0415.** 

**4,6-Di(thiophen-2-yl)pyridin-2(1***H***)-one (2u).** The title compound **2u** was obtained from (*E*)-1,3-di(thiophen-2-yl)-2-

propen-1-one **1u** (1.0 mmol) as a shiny brown solid (0.218 g, 84% yield); mp 244–247 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.39 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.87 (dd, *J* = 18.5, 3.1 Hz, 2H), 7.71 (dd, *J* = 21.8, 4.9 Hz, 2H), 7.29 (s, 1H), 7.23–7.17 (m, 2H), 6.65 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>)  $\delta$  164.1, 145.2, 140.6, 129.2, 128.9, 128.8, 127.4, 126.8, 115.9, 104.7 (<sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>)  $\delta$  164.1, 145.2, 140.6, 129.2, 128.9, 128.8, 127.4, 126.8, 115.9, 104.7); IR (KBr): 3448.61, 1637.58 cm<sup>-1</sup>; HRMS (ESI): calcd for C<sub>13</sub>H<sub>10</sub>NOS<sub>2</sub> [M + H]<sup>+</sup>, 260.0198; found: 260.0217.

**Ethyl** 2-nitro-5-oxo-3,5-diphenylpentanoate (3). White solid (30% yield); mp 114–116 °C (lit.<sup>10</sup> 116–117 °C); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.92–7.81 (m, 2H), 7.56–7.49 (m, 1H), 7.43–7.38 (m, 2H), 7.29–7.20 (m, 5H), 5.55 (d, *J* = 8.0 Hz, 1H), 4.53–4.46 (m, 1H), 4.24–4.03 (m, 2H), 3.74–3.51 (m, 2H), 1.09 (t, *J* = 8.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  196.2, 163.2, 136.9, 136.3, 133.4, 128.9, 128.7, 128.4, 128.3, 128.1, 128.0, 91.6, 63.0, 41.8, 40.4, 13.6; MS (ESI): *m/z* = 342 (M + H)<sup>+</sup>.

**3,4-Dihydro-3-nitro-4,6-diphenylpyridin-2(1***H***)-one (4). Shiny yellow solid (23% yield); mp 244–245 °C; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) \delta 10.58 (br s, 1H, exchangeable with D<sub>2</sub>O), 7.85–7.56 (m, 3H), 7.41–7.36 (m, 7H), 6.27 (d,** *J* **= 12 Hz, 1H), 5.46 (s, 1H), 4.67 (d,** *J* **= 16 Hz, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) \delta 162.3, 138.3, 136.7, 133.19, 128.9, 128.8, 128.4, 127.83, 126.7, 125.6, 105.0, 89.6, 43.2; MS (ESI):** *m***/***z* **= 295 (M + H)<sup>+</sup>.** 

Synthesis of 4,6-diarylated/heterylated pyridin-2-yl sulfonates 6a–h (general procedure B). 4,6-Disubstituted pyridin-2 (1*H*)-ones (100 mg, 0.404 mmol), *p*-toluenesulfonyl chloride (92.3 mg, 0.485 mmol), triethylamine (112.2 µL, 0.809 mmol) and 4-(*N*,*N*-dimethylamino) pyridine (1.3 mg, 0.012 mmol) were added into a 25 mL round-bottom flask containing 1 mL of analytical-grade CH<sub>2</sub>Cl<sub>2</sub>. After stirring at 25 °C for 10–15 h, the reaction mixture was diluted with water (50 mL) and extracted with Et<sub>2</sub>O (50 mL × 2). The organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and then concentrated on a rotary evaporator. The resulting residue was purified by silica gel flash chromatography (ethyl acetate/hexane 1:5 to 1:3) to afford the title compound (80–90%) (**6a–h**).

**4,6-Diphenylpyridin-2-yl 4-methylbenzenesulfonate (6a).** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.98 (d, J = 8.2 Hz, 2H), 7.83 (s, 1H), 7.76 (dd, J = 6.5, 2.9 Hz, 2H), 7.65 (d, J = 6.4 Hz, 2H), 7.50 (m, 3H), 7.42–7.39 (m, 3H), 7.37 (d, J = 8.2 Hz, 2H), 7.25 (s, 1H), 2.48 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  157.7, 156.5, 153.8, 145.0, 137.5, 137.4, 134.4, 129.6, 129.6, 129.2, 128.8, 128.6, 127.1, 127.0, 117.0, 111.6, 21.7; MS (ESI): m/z = 401.2.

6-(4-Chlorophenyl)-4-phenylpyridin-2-yl 4-methyl benzene sulfonate (6b). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.90 (d, *J* = 8.3 Hz, 2H), 7.71 (s, 1H), 7.67 (dd, *J* = 6.6, 2.9 Hz, 2H), 7.52 (d, *J* = 8.5 Hz, 2H), 7.41 (d, *J* = 8.5 Hz, 2H), 7.37–7.28 (m, 5H), 7.16 (s, 1H), 2.41 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  156.7, 155.7, 151.4, 144.1, 136.3, 134.9, 134.7, 133.3, 128.7, 128.5, 128.4, 127.8, 127.6, 127.3, 125.9, 115.7, 110.4, 20.7; MS (ESI): *m*/*z* = 436.1.

6-(4-Methoxyphenyl)-4-(4-methylphenyl)pyridin-2-yl 4-methyl benzenesulfonate (6c). <sup>1</sup>H NMR (400 MHz,  $CDCl_3$ )  $\delta$  7.97 (d, J = 8.3 Hz, 2H), 7.74 (d, J = 1.1 Hz, 1H), 7.71 (d, J = 8.9 Hz, 2H), 7.55 (d, J = 8.1 Hz, 2H), 7.37 (d, J = 8.1 Hz, 2H), 7.31 (d, J = 7.9 Hz, 2H), 7.16 (d, J = 1.0 Hz, 1H), 6.91 (d, J = 8.9 Hz, 2H), 3.87 (s, 3H), 2.48 (s, 3H), 2.43 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  160.8, 157.6, 156.1, 153.6, 144.9, 139.8, 134.6, 134.5, 130.3, 129.9, 129.5, 128.8, 128.3, 126.9, 115.9, 113.9, 110.5, 55.4, 21.7, 21.3; MS (ESI): m/z = 445.3.

**6-(Benzo[d]**[1,3]dioxol-5-yl)-4-phenylpyridin-2-yl 4-methyl benzenesulfonate (6d). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.96 (d, J = 8.3 Hz, 2H), 7.72 (s, 1H), 7.64 (dd, J = 7.8, 1.5 Hz, 2H), 7.50 (d, J = 7.6 Hz, 3H), 7.39 (d, J = 8.1 Hz, 2H), 7.31 (dd, J = 8.2, 1.7 Hz, 1H), 7.20 (s, 1H), 7.11 (d, J = 1.6 Hz, 1H), 6.82 (d, J = 8.2Hz, 1H), 6.02 (s, 2H), 2.49 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 156.5, 154.9, 152.7, 147.8, 147.1, 144.1, 136.3, 133.4, 130.9, 128.6, 128.1, 127.7, 126.0, 120.0, 115.3, 110.1, 107.1, 106.3, 100.3, 20.6; MS (ESI): m/z = 445.1.

6-Phenyl-4-(3,4,5-trimethoxyphenyl)pyridin-2-yl 4-methyl benzenesulfonate (6e). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.99 (d, J = 8.2 Hz, 2H), 7.77 (s, 1H), 7.76–7.72 (m, 2H), 7.43–7.40 (m, 3H), 7.38 (d, J = 8.2 Hz, 2H), 7.21 (s, 1H), 6.83 (s, 2H), 3.96 (s, 6H), 3.92 (s, 3H), 2.49 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 157.6, 156.4, 153.8, 153.7, 145.1, 139.3, 137.4, 134.4, 133.0, 129.6, 128.8, 128.6, 127.0, 116.9, 111.5, 104.3, 60.9, 56.3, 21.7; MS (ESI): m/z = 491.4.

**6-(4-Methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)pyridin-2-yl 4-methylbenzenesulfonate (6f).** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.82 (d, *J* = 8.3 Hz, 2H), 7.59 (s, 1H), 7.57 (d, *J* = 1.9 Hz, 2H), 7.23 (d, *J* = 8.1 Hz, 2H), 6.97 (d, *J* = 1.0 Hz, 1H), 6.77 (d, *J* = 8.9 Hz, 2H), 6.69 (s, 2H), 3.81 (s, 6H), 3.79 (s, 3H), 3.70 (s, 3H), 2.33 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 160.9, 157.5, 156.2, 153.7, 145.0, 139.3, 134.5, 133.1, 130.0, 129.6, 128.7, 128.3, 115.9, 113.9, 110.6, 104.4, 60.9, 56.3, 55.3, 21.7; MS (ESI): *m*/*z* = 521.2.

**4-(Furan-2-yl)-6-phenylpyridin-2-yl 4-methylbenzenesulfonate** (6g). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.96 (d, J = 8.3 Hz, 2H), 7.87 (s, 1H), 7.73 (dd, J = 6.7, 3.0 Hz, 2H), 7.58 (d, J = 1.2 Hz, 1H), 7.42–7.39 (m, 3H), 7.36 (d, J = 8.2 Hz, 2H), 7.32–7.21 (m, 1H), 6.95 (d, J = 3.4 Hz, 1H), 6.56 (dd, J = 3.4, 1.8 Hz, 1H), 2.47 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  157.7, 156.6, 150.5, 145.0, 144.3, 142.3, 137.4, 134.3, 129.6, 129.6, 128.8, 128.6, 126.9, 112.9, 112.3, 109.9, 107.7, 21.7; MS (ESI): m/z = 391.3.

**4,6-Di**(thiophen-2-yl)pyridin-2-yl 4-methylbenzenesulfonate (6h). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.02 (d, J = 8.3 Hz, 2H), 7.66 (d, J = 1.0 Hz, 1H), 7.56–7.50 (m, 2H), 7.49–7.44 (m, 1H), 7.39 (dd, J = 8.1, 4.3 Hz, 3H), 7.18–7.14 (m, 1H), 7.14 (d, J = 1.0 Hz, 1H), 7.08 (dd, J = 4.9, 3.8 Hz, 1H), 2.47 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  157.6, 152.0, 146.4, 145.1, 142.9, 139.9, 134.1, 129.6, 128.9, 128.6, 128.44, 128.0, 126.3, 125.8, 113.6, 109.3, 21.7; MS (ESI): m/z = 413.12.

Synthesis of 2,4,6-triaryl/heteryl pyridine derivatives 7a–i (general procedure C). A sealed tube (50.0 mL), fitted with a septum, containing  $Pd(OAc)_2$  (7.2 mg, 0.1 mmol) and XPhos (15.5 mg, 0.1 mmol) was evacuated and purged with nitrogen. 2,4-Diarylated pyridine-2-yl sulfonate (1.0 mmol), arylboronic acid (1.2 mmol), NaOH (2.0 equiv.), and *n*BuOH/EtOH/H<sub>2</sub>O (6/1/1, 1.0 mL) were added to the system and the reaction

mixture was stirred at 100 °C for 12 h. Upon completion of the reaction, the mixture was cooled to room temperature, extracted with ethyl acetate (25 mL  $\times$  2), and washed with water. The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum. The crude product was purified by silica gel column chromatography (hexane/EtOAc, 98:2) to provide the desired products (7**a**–**i**).

**2,4,6-Triphenylpyridine** (7a). The title compound 7a was obtained from 4,6-diphenylpyridin-2-yl 4-methylbenzenesulfonate 6a (1.0 mmol) as a white solid (49.8 mg, 65% yield); mp 130–132 °C (lit.<sup>22</sup> 134–135 °C); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.22 (d, J = 1.4 Hz, 2H), 8.20 (d, J = 5.0 Hz, 2H), 7.89 (s, 1H), 7.76 (d, J = 1.5 Hz, 1H), 7.74 (s, 1H), 7.56–7.52 (m, 5H), 7.49 (d, J = 4.0 Hz, 2H), 7.47–7.41 (m, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  157.5, 150.2, 139.6, 139.1, 129.1, 129.1, 129.0, 128.7, 127.2, 127.2, 117.1; HRMS (ESI): calcd for C<sub>23</sub>H<sub>18</sub>N [M + H]<sup>+</sup>, 308.1434; found: 308.1436.

2-(4-Chlorophenyl)-4-phenyl-6-(4-methylphenyl)pyridine (7b). The title compound 7b was obtained from 6-(4-chlorophenyl)-4-phenylpyridin-2-yl 4-methylbenzenesulfonate 6b (1.0 mmol) as a white solid (40.5 mg, 62% yield); mp 164–167 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.14 (d, J = 8.5 Hz, 2H), 8.08 (d, J = 8.1 Hz, 2H), 7.86 (s, 1H), 7.82 (s, 1H), 7.73 (d, J = 7.0 Hz, 2H), 7.53 (t, J = 7.2 Hz, 2H), 7.48 (dd, J = 7.6, 3.9 Hz, 3H), 7.32 (d, J = 8.0 Hz, 2H), 2.43 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  157.6, 156.1, 150.3, 139.2, 139, 138.1, 136.6, 135.1, 129.5, 129.4, 129.1, 129, 128.8, 128.8, 128.4, 127.1, 126.1, 117, 116.5, 21.3; HRMS (ESI): calcd for C<sub>24</sub>H<sub>19</sub>ClN [M + H]<sup>+</sup>, 356.1201; found: 356.1197.

**2-(3-Methoxyphenyl)-6-(4-methoxyphenyl)-4-(4-methylphenyl) pyridine (7c).** The title compound 7c was obtained from 6-(4-methoxyphenyl)-4-(4-methylphenyl)pyridin-2-yl 4-methylbenzene sulfonate 6c (1.0 mmol) as a white solid (0.210 g, 60% yield); mp 144–148 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.06 (d, J = 8.3 Hz, 2H), 7.70 (s, 3H), 7.64 (d, J = 7.6 Hz, 1H), 7.53 (d, J = 7.9 Hz, 2H), 7.31 (t, J = 7.9 Hz, 1H), 7.21 (d, J = 7.8 Hz, 2H), 6.92 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 8.2 Hz, 1H), 3.81 (s, 3H), 3.76 (s, 3H), 2.32 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.50, 159.00, 156.00, 155.97, 148.89, 140.30, 137.94, 135.15, 131.23, 128.75, 128.58, 127.35, 125.94, 118.50, 115.34, 115.18, 113.48, 113.01, 111.71, 54.34, 54.30, 20.19; HRMS (ESI): calcd for C<sub>26</sub>H<sub>24</sub>NO<sub>2</sub> [M + H]<sup>+</sup>, 382.1802; found: 382.1799.

**2,6-Bis(benzo[d]**[1,3]**dioxol-5-yl)-4-phenylpyridine** (7**d**). The title compound 7**d** was obtained from 6-(benzo[d][1,3]dioxol-5-yl)-4-phenylpyridin-2-yl 4-methylbenzenesulfonate **6d** (1.0 mmol) as a white solid (79.9 mg, 60% yield); mp 142–146 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.74 (m, 4H), 7.73 (d, J = 1.5 Hz, 1H), 7.71–7.69 (m, 2H), 7.67 (d, J = 1.7 Hz, 1H), 7.54–7.52 (m, 2H), 7.49–7.46 (m, 1H), 6.93 (d, J = 8.1 Hz, 2H), 6.04 (s, 4H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$  156.7, 150.1, 148.5, 148.2, 139.1, 134.0, 129.1, 128.9, 127.1, 121.0, 116.1, 108.3, 107.6, 101.3; HRMS (ESI): calcd for C<sub>25</sub>H<sub>18</sub>NO<sub>4</sub> [M + H]<sup>+</sup>, 396.1231; found: 396.1230.

**2,6-Diphenyl-4-(3,4,5-trimethoxyphenyl)pyridine** (7e). The title compound 7e was obtained from 6-phenyl-4-(3,4,5-tri-

methoxyphenyl)pyridin-2-yl 4-methylbenzenesulfonate **6e** (1.0 mmol) as a white solid (53.5 mg, 55% yield); mp 108–109 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.13 (d, J = 1.4 Hz, 2H), 8.11 (d, J = 1.3 Hz, 2H), 7.74 (s, 2H), 7.48–7.41 (m, 4H), 7.39 (m, 1H), 7.36 (d, J = 7.3 Hz, 1H), 6.83 (s, 2H), 3.89 (s, 6H), 3.85 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  156.5, 152.7, 149.4, 138.5, 138.0, 133.9, 128.0, 127.6, 126.1, 116.0, 103.6, 59.9, 55.3; HRMS (ESI): calcd for C<sub>27</sub>H<sub>24</sub>NO<sub>3</sub> [M + H]<sup>+</sup>, 398.1751; found: 398.1751.

**2-(Benzo[d]**[1,3]dioxol-5-yl)-6-phenyl-4-(3,4,5-trimethoxyphenyl)pyridine (7f). The title compound 7f was obtained from 6-(4-methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)pyridin-2-yl 4-methyl benzenesulfonate **6e** (1.0 mmol) as a white solid (45.1 mg, 50% yield); mp 149–151 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.08 (d, J = 8.2 Hz, 2H), 7.68 (s, 2H), 7.63 (s, 1H), 7.60 (dd, J = 8.1, 1.6 Hz, 1H), 7.42 (m, 2H), 7.36 (d, J = 7.9 Hz, 1H), 6.84 (d, J = 8.1 Hz, 1H), 6.80 (s, 2H), 5.94 (s, 2H), 3.87 (s, 6H), 3.84 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  157.3, 156.9, 153.8, 150.4, 148.5, 148.2, 139.5, 135.0, 134.0, 129.0, 128.7, 127.1, 121.1, 116.7, 116.4, 108.3, 107.6, 104.6, 101.3, 61.0, 56.4; HRMS (ESI): calcd for C<sub>27</sub>H<sub>24</sub>NO<sub>5</sub> [M + H]<sup>+</sup>, 442.1649; found: 442.1651.

**2,6-Bis(4-methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)pyridine** (7g). The title compound 7g was obtained from 6-(4-methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)pyridin-2-yl 4-methyl benzenesulfonate **6f** (1.0 mmol) as a liquid (23.7 mg, 50% yield); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.06 (d, J = 8.8 Hz, 4H), 7.61 (s, 2H), 6.94 (d, J = 8.8 Hz, 4H), 6.80 (s, 2H), 3.87 (s, 6H), 3.84 (s, 3H), 3.78 (s, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  159.5, 155.9, 152.7, 149.3, 137.9, 134.2, 131.1, 127.4, 114.7, 113.0, 103.5, 59.9, 55.3, 54.3; HRMS (ESI): calcd for C<sub>28</sub>H<sub>28</sub>NO<sub>5</sub> [M + H]<sup>+</sup>, 458.1962; found: 458.1959.

**4-(4-(Furan-2-yl)-6-phenylpyridin-2-yl)benzonitrile** (7h). The title compound 7h was obtained from 4-(furan-2-yl)-6-phenylpyridin-2-yl 4-methylbenzenesulfonate **6g** (1.0 mmol) as a white solid (48.2 mg, 65% yield); mp 154–156 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.15 (d, *J* = 8.4 Hz, 2H), 8.04 (d, *J* = 7.0 Hz, 2H), 7.83 (d, *J* = 0.9 Hz, 1H), 7.78 (d, *J* = 0.9 Hz, 1H), 7.65 (d, *J* = 8.4 Hz, 2H), 7.49 (d, *J* = 1.2 Hz, 1H), 7.42–7.37 (m, 3H), 6.87 (d, *J* = 3.3 Hz, 1H), 6.48 (dd, *J* = 3.4, 1.7 Hz, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) δ 157.8, 155.1, 151.4, 143.9, 143.4, 139.3, 138.8, 132.4, 129.4, 128.8, 127.5, 127.0, 118.9, 113.9, 113.3, 112.4, 112.3, 109.0; HRMS (ESI): calcd for C<sub>22</sub>H<sub>15</sub>N<sub>2</sub>O [M + H]<sup>+</sup>, 323.1179; found: 323.1175.

**4,6-Di(thiophen-2-yl)-2,3'-bipyridine** (7i). The title compound 7i was obtained from 4,6-di(thiophen-2-yl)pyridin-2-yl 4-methyl benzenesulfonate **6h** (1.0 mmol) as a white solid (31.5 mg, 58% yield); mp 164–167 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  9.34 (s, 1H), 8.69 (d, J = 3.6 Hz, 1H), 8.48 (d, J = 8.0 Hz, 1H), 7.81 (s, 1H), 7.80 (d, J = 1.2 Hz, 1H), 7.73 (d, J = 4.5 Hz, 1H), 7.62 (s, 1H), 7.46 (dd, J = 8.7, 6.0 Hz, 2H), 7.21–7.10 (m, 2H), 6.98 (s, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  154.9, 153.3, 150.0, 148.2, 145.7, 144.7, 143.3, 134.5, 128.5, 128.1, 128.0, 127.3, 125.6, 125.0, 123.6, 120.2, 114.9, 114.1; HRMS (ESI): calcd for C<sub>18</sub>H<sub>13</sub>N<sub>2</sub>S<sub>2</sub> [M + H]<sup>+</sup>, 321.0515; found: 321.0512.

### Acknowledgements

R. K., P. K., A. G., G. R. and A. K. J. thank to UGC, CSIR, DST-New Delhi, India for their research fellowships.

### Notes and references

- (a) W. Adam, J. Hartung, H. Okamoto, S. Marquardt, W. M. Nau, U. Pischel, C. R. Saha-Moller and K. Spehar, J. Org. Chem., 2002, 67, 6041; (b) F. Surup, O. Wagner, J. Frieling, M. Schleicher, S. Oess, P. Muller and S. Grond, J. Org. Chem., 2007, 72, 5085; (c) I. Collins, C. Moyes and W. B. Davey, J. Med. Chem., 2002, 45, 1887; (d) M. E. Wall, M. C. Wani, C. E. Cook, K. H. Palmer, A. McPhail and G. A. Sim, J. Am. Chem. Soc., 1966, 88, 3888; (e) H. Josien and D. P. Curran, Tetrahedron, 1997, 53, 8881.
- 2 J. M. Rawson and R. E. P. Winpenny, *Coord. Chem. Rev.*, 1995, **139**, 313.
- 3 (a) Z. A. E. Waller, P. S. Shirude, R. Rodriguez and S. Balasubramanian, *Chem. Commun.*, 2008, 1467;
  (b) B. Corry and N. M. Smith, *Chem. Commun.*, 2012, 48, 8958; (c) R. Karki, P. Thapa, H. Y. Yoo, T. M. Kadayat, P. H. Park, Y. Na, E. Lee, K. H. Jeon, W. J. Cho, H. Choi, Y. Kown and E. S. Lee, *Eur. J. Med. Chem.*, 2012, 49, 219;
  (d) N. M. Smith, G. Labrunie, B. Corry, P. L. T. Tran, M. Norret, M. Djavaheri-Mergny, C. L. Raston and J. L. Mergny, *Org. Biomol. Chem.*, 2011, 9, 6154.
- 4 (a) E. C. Constable, C. E. Housecroft, M. Neuburger,
  D. Phillips, P. R. Raithby, E. Schofield, E. Sparr,
  D. A. Tocher, M. Zehnder and Y. Zimmermann, *J. Chem. Soc., Dalton Trans.*, 2000, 13, 2219.
- 5 (a) F. Manna, F. Chimenti, A. Bolasco, W. Filippelli,
  A. Filippelli, A. Palla, E. Lampa and R. Mercantini, *Eur. J. Med. Chem.*, 1992, 27, 627; (b) F. Manna, F. Chimenti,
  A. Bolasco, B. Bizzarri, M. Botta, A. Tafi, A. Filippelli and
  S. Rossi, *Bioorg. Med. Chem. Lett.*, 2000, 10, 1883.
- 6 For synthesis of functionalised pyridin-2(1*H*)-ones, see:
  (*a*) G. Jones, Org. React., 1967, 15, 205; (*b*) L. Carles,
  K. Narkunan, S. Penlou, L. Rousset, D. Bouchu and
  M. A. Ciufolini, J. Org. Chem., 2002, 67, 4304; (*c*) I. Hachiya,
  K. Ogura and M. Shimizu, Org. Lett., 2002, 4, 2755;
  (*d*) S. Pathak, A. Kundu and A. Pramanik, Tetrahedron Lett.,
  2012, 53, 3030; (*e*) J. S. Siddle, A. S. Batsanov,
  S. T. Caldwell, G. Cooke and M. R. Bryce, Tetrahedron, 2010,
  66, 6138; (*f*) L. Ackermann, A. V. Lygin and N. Hofmann,
  Org. Lett., 2011, 13, 3278.
- 7 For synthesis of 4,6-diarylated pyridin-2(1*H*)-ones from 1,3-diarylated-2-propen-1-ones, see: (a) A. R. Katritzky, S. A. Belyakov, A. E. Sorochinsky, S. A. Henderson and J. Chen, J. Org. Chem., 1997, 62, 6210; (b) S. Wang, G. Yu, J. Lu, K. Xiao, Y. Hu and H. Hu, Synthesis, 2003, 487; (c) M. Fujii, T. Nishimura, T. Koshiba, S. Yokoshima and T. Fukuyama, Org. Lett., 2013, 15, 232.
- 8 (*a*) K. K. Kapoor, S. Kumar and B. A. Ganai, *Tetrahedron Lett.*, 2005, **46**, 6253; (*b*) A. K. Verma, S. Koul, T. K. Razdan

and K. K. Kapoor, *Can. J. Chem.*, 2006, **84**, 1064; (c) A. K. Verma, S. Kumar and K. K. Kapoor, *Aust. J. Chem.*, 2007, **60**, 621; (d) T. Naqvi, D. Mahajan, R. L. Sharma, I. A. Khan and K. K. Kapoor, *J. Heterocycl. Chem.*, 2011, **48**, 144.

- 9 (a) R. Khajuria, Y. Saini and K. K. Kapoor, *Tetrahedron Lett.*, 2013, 54, 5699; (b) R. Khajuria and K. K. Kapoor, *Curr. Microwave Chem.*, 2014, 1, 110.
- 10 W. Davey and D. J. Tivey, J. Chem. Soc., 1958, 2276.
- 11 (a) B. Bhayana, B. P. Fors and S. L. Buchwald, Org. Lett., 2009, 11, 3954; (b) J. Yang, S. Liu, J.-F. Zheng and J. Zhou, Eur. J. Org. Chem., 2012, 6248; (c) Z.-J. Quan, F.-Q. Jing, Z. Zhang, Y.-X. Da and X.-C. Wang, Eur. J. Org. Chem., 2013, 7175; (d) T. Abe, T. Mino, K. Watanabe, F. Yagishita and M. Sakamoto, Eur. J. Org. Chem., 2014, 3909; (e) L.-C. Campeau, S. Rousseaux and K. Fagnou, J. Am. Chem. Soc., 2005, 127, 18020; (f) L. Ackermann, A. R. Kapdi, S. Fenner, C. Kornhaa and C. Schulzke, Chem. Eur. J., 2011, 17, 2965; (g) S. A. Glase, A. E. Corbin, T. A. Pugsley, T. G. Heffner and L. D. Wise, J. Med. Chem., 1995, 38, 3132; (h) P. P. Yeh, D. S. B. Daniels, D. B. Cordes, A. M. Z. Slawin and A. D. Smith, Org. Lett., 2014, 16, 964.
- 12 (a) L. M. Daykin, J. S. Siddle, A. L. Ankers, A. S. Batsanov and M. R. Bryce, *Tetrahedron*, 2010, 66, 668;
  (b) C. Doebelin, P. Wagner, F. Bihel, N. Humbert, C. A. Kenfack, Y. Mely, J.-J. Bourguignon and M. Schmitt, *J. Org. Chem.*, 2014, 79, 908.
- 13 (a) V. F. Slagt, A. H. M. de Vries, J. G. de Vries and R. M. Kellogg, *Org. Process Res. Dev.*, 2010, 14, 30;
  (b) J.-P. Corbet and G. R. Mignani, *Chem. Rev.*, 2006, 106, 2651; (c) H. Li, C. C. C. Johansson Seechurn and T. J. Colacot, *ACS Catal.*, 2012, 2, 1147.
- 14 (a) T. Mesganaw and N. K. Garg, Org. Process Res. Dev., 2013, 17, 29; (b) D.-G. Yu, B.-J. Li and Z.-J. Shi, Acc. Chem. Res., 2010, 43, 1486; (c) C. M. So and F. Y. Kwong, Chem. Soc. Rev., 2011, 40, 4963; (d) J. Cornella, C. Zarate and R. Martin, Chem. Soc. Rev., 2014, 43, 8081.
- 15 (a) D. D. Vachhani, A. Sharma and V. E. Eycken, J. Org. Chem., 2012, 77, 8768; (b) L. Liao, R. Jana, K. B. Urkalanand and M. S. Sigman, J. Am. Chem. Soc., 2011, 133, 5784.
- 16 (a) D. A. Wilson, C. J. Wilson, B. M. Rosen and V. Percec, Org. Lett., 2008, 10, 4879; (b) C. M. So, C. P. Lau, A. S. C. Chan and F. Y. Kwang, J. Org. Chem., 2008, 73, 7731; (c) S. Fan, J. Yang and X. Zhang, Org. Lett., 2011, 13, 4374; (d) D. G. Stark, L. C. Morrill, P.-P. Yeh, A. M. Z. Slawin, T. J. C. O'Riordan and A. D. Smith, Angew. Chem., Int. Ed., 2013, 52, 11646; (e) L. Ackermann and A. Althammer, Org. Lett., 2006, 8, 3457.
- 17 (a) T. M. Gogsig, A. T. Lindhardt, M. Dekhane, J. Grouleff and T. Skrydstrup, *Chem. – Eur. J.*, 2009, **15**, 5950;
  (b) T. Ogata and J. F. Hartwig, *J. Am. Chem. Soc.*, 2008, **130**, 13848.
- 18 (a) I. V. Magedov, L. Frolova, M. Manapudi, U. D. Bhoga, H. Tang, N. M. Evdokimov, O. George, K. H. Georgiou, S. Renner, M. U. Getlik, T. L. Kinnibrugh, M. A. Fernandes,

S. Van Slambrouck, W. F. A. Steelant, C. B. Shuster, S. Rogelj, W. A. L. van Otterlo and A. Kornienko, *J. Med. Chem.*, 2011, **54**, 4234; (*b*) P. Thapa, R. Karki, U. Thapa, Y. Jahng, M.-J. Jung, J. M. Nam, Y. Na, Y. Kwon and E.-S. Lee, *Bioorg. Med. Chem.*, 2010, **18**, 377; (*c*) R. Karki, P. Thapa, M. J. Kang, T. C. Jeong, J. M. Nam, H.-L. Kim, Y. Na, W.-J. Cho, Y. Kwon and E.-S. Lee, *Bioorg. Med. Chem.*, 2010, **18**, 3066; (*d*) A. Basnet, P. Thapa, R. Karki, H. Choi, J. H. Choi, M. Yun, B.-S. Jeong, Y. Jahng, Y. Na, W.-J. Cho, Y. Kwon, C.-S. Lee and E.-S. Lee, *Bioorg. Med. Chem. Lett.*, 2010, **20**, 42.

- 19 G. A. Altomare, C. Giacovazzo and A. Guagliardi, J. Appl. Crystallogr., 1994, 27, 435.
- 20 G. M. Sheldrick, Acta Crystallogr., Sect. A: Found. Crystallogr., 2008, 64, 112.
- 21 (a) S. Ducki, R. Forrest, J. A. Hadfield, A. Kendall, N. J. Lawrence, A. T. McGown and D. Rennisonl, *Bioorg. Med. Chem. Lett.*, 1998, 8, 1051; (b) M.-Y. Chang and M.-H. Wu, *Tetrahedron*, 2012, 68, 9616; (c) M.-Y. Chang, M.-H. Wu and H.-Y. Tai, *Org. Lett.*, 2012, 14, 3936.
- 22 M. Adib, H. Tahermansouri, S. A. Koloogani, B. Mohammadi and H. R. Bijanzadeh, *Tetrahedron Lett.*, 2006, **47**, 5957.